Apr 8 |
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
|
Apr 2 |
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
|
Mar 29 |
Investors in Alkermes (NASDAQ:ALKS) have seen favorable returns of 44% over the past three years
|
Mar 25 |
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
Mar 25 |
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
|
Mar 19 |
Baird starts Alkermes at outperform, citing revenue stream
|
Mar 18 |
Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)
|
Mar 15 |
Alkermes (ALKS) Stock Moves -0.45%: What You Should Know
|
Mar 13 |
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
|
Mar 12 |
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
|